Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

89.94 +0.06 (+0.07%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,521,830
Open 90.30
Bid (Size) 89.80 (5)
Ask (Size) 90.49 (3)
Prev. Close 89.88
Today's Range 89.02 - 90.37
52wk Range 62.07 - 98.90
Shares Outstanding 1,253,809,440
Dividend Yield 3.42%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
From Gilead Sciences, Inc.
Via Business Wire
This McDonald's Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Via Benzinga

Performance

YTD
-2.11%
-2.11%
1 Month
-2.08%
-2.08%
3 Month
+5.75%
+5.75%
6 Month
+27.02%
+27.02%
1 Year
+4.59%
+4.59%

More News

Read More
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Via Benzinga
Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus
Via Benzinga
Looking Into Gilead Sciences's Recent Short Interest
Via Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today
Via Benzinga
(GILD) - Analyzing Gilead Sciences's Short Interest
Via Benzinga
Marjorie Taylor Greene Went Christmas Shopping For Stocks, Here's What She Bought Before Holiday
Via Benzinga
Healthcare And Biotech Stocks Continue Their Slide
Via Talk Markets
Topics ETFs Stocks / Equities
Based on good technical signals, GILEAD SCIENCES INC is potentially setting up for a breakout.
Via Chartmill
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Via Benzinga
Is GILEAD SCIENCES INC Ready to Break Out of Its Range?
Via Chartmill
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Via Benzinga
What Analysts Are Saying About Gilead Sciences Stock
Via Benzinga
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
Via Investor's Business Daily
COVID-19 is Not the Same Disease for Everyone
Via Brandpoint
Topics Death
Exposures COVID-19 Death
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
From Gilead Sciences, Inc.
Via Business Wire
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
From Gilead Sciences, Inc.
Via Business Wire
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Via Benzinga
Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
From Gilead Sciences, Inc.
Via Business Wire
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
Via Benzinga
Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
From Gilead Sciences, Inc.
Via Business Wire
Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
From Gilead Sciences, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.